Ganirelix Acetate NDC 70700-327

NDC codes

FDA NDC Directory

Product NDC (as listed)70700-327Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70700-0327Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70700-327-98	70700032798	1 SYRINGE, GLASS in 1 CARTON (70700-327-98) / 1 mL in 1 SYRINGE, GLASSMarketed from Apr 1, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ganirelix Acetate
Generic name (nonproprietary): ganirelix acetate
Active ingredients: Ganirelix acetate — 250 ug/.5mL
Dosage form: Injection
Route: Subcutaneous
Labeler: Xiromed LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215658
Marketing start: Apr 1, 2024
Listing expires: Dec 31, 2027
Other FDA classes: Decreased GnRH Secretion (Physiologic effect)Gonadotropin Releasing Hormone Receptor Antagonists (Mechanism)
Identifiers: Product ID 70700-327_4d50b641-9fb3-cb88-e063-6394a90a7b88SPL ID 4d50b641-9fb3-cb88-e063-6394a90a7b88SPL set ID 37a8e041-9751-665a-1965-765f7ff21922RxCUI 855200UNII 56U7906FQW
Pharmacologic class: Gonadotropin Releasing Hormone Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N470700032798 followed by a unit qualifier and the quantity

Package 70700-0327-98. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 18, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Ganirelix Acetate Injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215658

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215658
Product	Strength	Form · route	Labeler	Product NDC
Ganirelix Acetate	Ganirelix acetate 250 ug/.5mL	Injection, SolutionSubcutaneous	Gland Pharma Limited	68083-472
Ganirelix Acetate	Ganirelix acetate 250 ug/.5mL	InjectionSubcutaneous	Fresenius Kabi USA, LLC	65219-028